美国 · SEC FORM 4
REVELATION BIOSCIENCES, INC.
REVB · Nasdaq · CIK 0001810560 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
8 同一窗口内观察到的 Form 4 交易行
0 sales · 8 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
—
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2023-04-18 · TIDMARSH GEORGE F.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 1,581
- 上期报告
- 256
- 日均成交量
- 36,220
- 回补天数
- ≤ 1.0
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2023-04-18 | TIDMARSH GEORGE F | 买入 (P) | Common Stock | 25,000 | USD 1.16 | USD 29,000 | SEC 申报 ↗ |
| 2023-04-17 | TIDMARSH GEORGE F | 买入 (P) | Common Stock | 26,500 | USD 1.16 | USD 30,740 | SEC 申报 ↗ |
| 2022-02-25 | TIDMARSH GEORGE F | 买入 (P) | Common Stock | 20,000 | USD 1.60 | USD 32,000 | SEC 申报 ↗ |
| 2022-02-09 | TIDMARSH GEORGE F | 买入 (P) | Common Stock | 30,000 | USD 2.55 | USD 76,500 | SEC 申报 ↗ |
| 2022-02-08 | TIDMARSH GEORGE F | 买入 (P) | Common Stock | 1,000 | USD 2.54 | USD 2,540 | SEC 申报 ↗ |
| 2022-02-07 | TIDMARSH GEORGE F | 买入 (P) | Common Stock | 42,100 | USD 2.61 | USD 109,881 | SEC 申报 ↗ |
| 2022-02-07 | TIDMARSH GEORGE F | 买入 (P) | Common Stock | 42,100 | USD 2.61 | USD 109,881 | SEC 申报 ↗ |
| 2022-02-04 | TIDMARSH GEORGE F | 买入 (P) | Common Stock | 9,900 | USD 2.34 | USD 23,149 | SEC 申报 ↗ |
| 2022-02-04 | TIDMARSH GEORGE F | 买入 (P) | Common Stock | 7,900 | USD 2.31 | USD 18,249 | SEC 申报 ↗ |
Form 4 申报证据
23 transaction lines in the latest 365-day window; 56 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-17 | Zygmont Chester Stanley III | 赠与 (G) | Common Stock | 208,073 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-17 | Zygmont Chester Stanley III | 奖励／授予 (A) | Common Stock | 208,073 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-17 | Rolke James | 奖励／授予 (A) | Common Stock | 208,076 | USD 0.00 | USD 0 | SEC 申报 ↗ |
展开近期 Form 4 证据 (23 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-17 | Zygmont Chester Stanley III | 赠与 (G) | Common Stock | 208,073 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-17 | Zygmont Chester Stanley III | 奖励／授予 (A) | Common Stock | 208,073 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-17 | Rolke James | 奖励／授予 (A) | Common Stock | 208,076 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-17 | ROPER JESS | 奖励／授予 (A) | Common Stock | 32,011 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-17 | Chawla Lakhmir S | 奖励／授予 (A) | Common Stock | 32,011 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-17 | CARVER JENNIFER | 奖励／授予 (A) | Common Stock | 32,011 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-04-30 | Zygmont Chester Stanley III | 代扣税 (F) | Common Stock | 13,285 | USD 1.10 | USD 14,614 | SEC 申报 ↗ |
| 2026-04-30 | Rolke James | 代扣税 (F) | Common Stock | 10,115 | USD 1.13 | USD 11,430 | SEC 申报 ↗ |
| 2026-02-04 | Zygmont Chester Stanley III | 代扣税 (F) | Common Stock | 13,100 | USD 1.65 | USD 21,615 | SEC 申报 ↗ |
| 2026-02-03 | Rolke James | 代扣税 (F) | Common Stock | 8,521 | USD 1.86 | USD 15,849 | SEC 申报 ↗ |
| 2026-02-03 | ROPER JESS | 代扣税 (F) | Common Stock | 1,591 | USD 1.85 | USD 2,943 | SEC 申报 ↗ |
| 2026-02-03 | Chawla Lakhmir S | 代扣税 (F) | Common Stock | 2,261 | USD 1.85 | USD 4,183 | SEC 申报 ↗ |
| 2026-02-03 | CARVER JENNIFER | 代扣税 (F) | Common Stock | 1,661 | USD 1.87 | USD 3,106 | SEC 申报 ↗ |
| 2026-01-08 | Zygmont Chester Stanley III | 奖励／授予 (A) | Common Stock | 78,145 | USD 0.90 | USD 70,330 | SEC 申报 ↗ |
| 2026-01-08 | Rolke James | 奖励／授予 (A) | Common Stock | 532,829 | USD 0.90 | USD 479,546 | SEC 申报 ↗ |
| 2026-01-08 | ROPER JESS | 奖励／授予 (A) | Common Stock | 41,981 | USD 0.90 | USD 37,783 | SEC 申报 ↗ |
| 2026-01-08 | Chawla Lakhmir S | 奖励／授予 (A) | Common Stock | 41,981 | USD 0.90 | USD 37,783 | SEC 申报 ↗ |
| 2026-01-08 | CARVER JENNIFER | 奖励／授予 (A) | Common Stock | 41,981 | USD 0.90 | USD 37,783 | SEC 申报 ↗ |
| 2025-10-29 | Zygmont Chester Stanley III | 奖励／授予 (A) | Common Stock | 390,614 | USD 1.28 | USD 499,986 | SEC 申报 ↗ |
| 2025-10-29 | Rolke James | 奖励／授予 (A) | Common Stock | 390,614 | USD 1.28 | USD 499,986 | SEC 申报 ↗ |
| 2025-10-29 | ROPER JESS | 奖励／授予 (A) | Common Stock | 15,625 | USD 1.28 | USD 20,000 | SEC 申报 ↗ |
| 2025-10-29 | Chawla Lakhmir S | 奖励／授予 (A) | Common Stock | 15,625 | USD 1.28 | USD 20,000 | SEC 申报 ↗ |
| 2025-10-29 | CARVER JENNIFER | 奖励／授予 (A) | Common Stock | 15,625 | USD 1.28 | USD 20,000 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-19 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | REVB |
| CIK | 0001810560 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 56 transaction lines from 2020-10-09 to 2026-08-17 10 P purchase lines · 13 S sale lines · 33 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.